NVAX

Novavax is significantly undervalued post-COVID, with a current enterprise value around $716 million and a promising pipeline led by Matrix-M. NVAX's Matrix-M adjuvant is a core value driver, validated by major partnerships with Sanofi and Pfizer, offering substantial milestone and royalty upside. Revenue is now primarily driven by licensing and royalties, with product sales from Nuvaxovid declining sharply; partnership dependence is a key risk.

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

RALEIGH, N.C., June 24, 2026 (GLOBE NEWSWIRE) -- Shah Capital, the largest shareholder of Novavax, today commented on yesterday's announced voting results from Novavax's June 18th 2026 Annual Meeting of Stockholders.

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax (NVAX) closed the most recent trading day at $9.13, moving 3.89% from the previous trading session.

Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is jumping again.

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock?

Novavax, Inc. (NVAX) Presents at Jefferies Global Healthcare Conference 2026 Transcript